Your browser doesn't support javascript.
loading
Clinical Outcomes of Dose-Escalated Hypofractionated External Beam Radiation Therapy (5 Gy × 5 Fractions) for Spine Metastasis.
Shin, Jacob Y; Mathis, Noah J; Wijetunga, Neil Ari; Yerramilli, Divya; Higginson, Daniel S; Schmitt, Adam M; Gomez, Daniel R; Yamada, Yoshiya J; Yang, Jonathan T.
Afiliação
  • Shin JY; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Mathis NJ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Wijetunga NA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Yerramilli D; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Higginson DS; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Schmitt AM; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gomez DR; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Yamada YJ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Yang JT; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Adv Radiat Oncol ; 7(4): 100906, 2022.
Article em En | MEDLINE | ID: mdl-35287317
ABSTRACT

Purpose:

The objective of this study was to determine the toxicities and outcomes of patients with spinal metastasis treated with external beam radiation therapy (EBRT) to 25 Gy in 5 fractions. Methods and Materials Data were extracted from an institutional tumor registry for patients with spinal metastasis who were treated with EBRT to 25 Gy in 5 fractions to their spinal lesion(s). Cox regression and Kaplan-Meier analyses to determine local control and overall survival (OS) were employed.

Results:

Seventy-five patients with 86 total treated spinal metastatic tumors were identified. The median follow-up was 7 months. The median age was 66 years. Fifty-six patients (75.7%) experienced partial or complete pain relief for a median duration of 6 months (range, 1-33). Fifty-one (59.3%) cases were planned using intensity modulated radiation therapy while 19 (22.1%) employed 3-dimensional conformal radiation therapy and 16 (18.6%) cases used nonconformal radiation technique. Greater than 90% of cases had a point dose maximum to the spinal cord/cauda equina <27.5 Gy. No patient experienced treatment-related myelopathy. The most common toxicities were fatigue (23.3%), pain flare (14.0%), and nausea (8.1%). There were no grade 3 toxicities. One-year local control was 80.6%, and 1-year OS was 38.4%. Higher Karnofsky performance status (P = .001) and radiosensitive tumor histology (P = .014) were significant predictors for better OS.

Conclusions:

Our single-institutional retrospective analysis of patients with spinal metastasis suggested that palliative EBRT to 25 Gy in 5 fractions is safe, with a low toxicity profile and minimal risk for myelopathy with an achievable dose maximum to the spinal cord and cauda equina ≤27 Gy (equivalent total dose in 2-Gy fractions ≤50 Gy), and it may provide durable palliation and local control in cases where stereotactic body radiation therapy may not be indicated.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Adv Radiat Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Adv Radiat Oncol Ano de publicação: 2022 Tipo de documento: Article